Guangshun Sun

1.1k total citations
27 papers, 790 citations indexed

About

Guangshun Sun is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Guangshun Sun has authored 27 papers receiving a total of 790 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Guangshun Sun's work include Cancer Immunotherapy and Biomarkers (10 papers), Circular RNAs in diseases (4 papers) and Cancer-related molecular mechanisms research (4 papers). Guangshun Sun is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), Circular RNAs in diseases (4 papers) and Cancer-related molecular mechanisms research (4 papers). Guangshun Sun collaborates with scholars based in China and Germany. Guangshun Sun's co-authors include Weiwei Tang, Dawei Rong, Guoqiang Sun, Xuehao Wang, Xiaopei Hao, Ye Cheng, Fan Wu, Hongyong Cao, Zhouxiao Li and Wubin Zheng and has published in prestigious journals such as Frontiers in Immunology, Acta Biomaterialia and Frontiers in Oncology.

In The Last Decade

Guangshun Sun

27 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Guangshun Sun China 16 478 271 230 168 120 27 790
Wubin Zheng China 9 325 0.7× 262 1.0× 193 0.8× 165 1.0× 134 1.1× 12 618
Haihua Qian China 17 500 1.0× 311 1.1× 261 1.1× 140 0.8× 100 0.8× 29 828
Xiangyuan Luo China 11 391 0.8× 178 0.7× 151 0.7× 127 0.8× 111 0.9× 19 698
Peishan Hu China 16 564 1.2× 310 1.1× 172 0.7× 98 0.6× 133 1.1× 30 832
Sorin Armeanu–Ebinger Germany 16 467 1.0× 203 0.7× 241 1.0× 131 0.8× 105 0.9× 45 895
Tongyue Zhang China 16 418 0.9× 264 1.0× 189 0.8× 136 0.8× 120 1.0× 36 736
Zhouyu Ning China 19 500 1.0× 357 1.3× 364 1.6× 87 0.5× 134 1.1× 40 911
Alisha M. Mendonsa United States 7 478 1.0× 227 0.8× 268 1.2× 99 0.6× 89 0.7× 8 865
Huizhen Suo Germany 5 398 0.8× 239 0.9× 328 1.4× 101 0.6× 79 0.7× 7 730
Taisuke Kawamoto Japan 15 692 1.4× 464 1.7× 309 1.3× 144 0.9× 81 0.7× 31 989

Countries citing papers authored by Guangshun Sun

Since Specialization
Citations

This map shows the geographic impact of Guangshun Sun's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangshun Sun with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangshun Sun more than expected).

Fields of papers citing papers by Guangshun Sun

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangshun Sun. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangshun Sun. The network helps show where Guangshun Sun may publish in the future.

Co-authorship network of co-authors of Guangshun Sun

This figure shows the co-authorship network connecting the top 25 collaborators of Guangshun Sun. A scholar is included among the top collaborators of Guangshun Sun based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangshun Sun. Guangshun Sun is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rong, Dawei, Yuliang Wang, Li Liu, et al.. (2023). GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway. Journal for ImmunoTherapy of Cancer. 11(2). e005126–e005126. 17 indexed citations
2.
Sun, Guangshun, Hanyuan Liu, Jie Zhao, et al.. (2022). Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. Journal for ImmunoTherapy of Cancer. 10(12). e005655–e005655. 29 indexed citations
3.
Sun, Guoqiang, Zhitao Li, Chunguang Zhou, et al.. (2022). Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. Journal of Oncology. 2022. 1–16. 11 indexed citations
4.
Sun, Guangshun, Guoqiang Sun, Wubin Zheng, et al.. (2022). Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway. Journal of Oncology. 2022. 1–12. 8 indexed citations
5.
Li, Xiao, Liangliang Wu, Zhiying Zheng, et al.. (2022). Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy. Journal of Oncology. 2022. 1–12. 4 indexed citations
6.
Rong, Dawei, Guangshun Sun, Zhiying Zheng, et al.. (2022). MGP promotes CD8+ T cell exhaustion by activating the NF-κB pathway leading to liver metastasis of colorectal cancer. International Journal of Biological Sciences. 18(6). 2345–2361. 70 indexed citations
7.
Li, Xiao, Yuetong Zhao, Hanyuan Liu, et al.. (2022). Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomaterialia. 157. 337–351. 23 indexed citations
8.
Kong, Xiangyi, Zhiying Zheng, Guoxin Song, et al.. (2022). Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma. Frontiers in Immunology. 13. 876048–876048. 12 indexed citations
9.
Li, Xiao, Guangshun Sun, Liangliang Wu, et al.. (2021). Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target. Journal of Oncology. 2021. 1–18. 12 indexed citations
10.
Rong, Dawei, Guangshun Sun, Fan Wu, et al.. (2021). Epigenetics: Roles and therapeutic implications of non-coding RNA modifications in human cancers. Molecular Therapy — Nucleic Acids. 25. 67–82. 65 indexed citations
11.
Rong, Dawei, Fan Wu, Lu Chen, et al.. (2021). m6A modification of circHPS5 and hepatocellular carcinoma progression through HMGA2 expression. Molecular Therapy — Nucleic Acids. 26. 637–648. 77 indexed citations
12.
Zheng, Wubin, Fan Wu, Kai Fu, et al.. (2021). Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer. OncoTargets and Therapy. Volume 14. 3013–3036. 15 indexed citations
13.
Hao, Xiaopei, Yao Zhang, Yiwei Lu, et al.. (2021). STK39 enhances the progression of Cholangiocarcinoma via PI3K/AKT pathway. iScience. 24(11). 103223–103223. 9 indexed citations
14.
Li, Zhitao, Wubin Zheng, Hanjin Wang, et al.. (2021). Application of Animal Models in Cancer Research: Recent Progress and Future Prospects. Cancer Management and Research. Volume 13. 2455–2475. 70 indexed citations
15.
Sun, Guangshun, Zhouxiao Li, Dawei Rong, et al.. (2021). Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges. Molecular Therapy — Oncolytics. 21. 183–206. 53 indexed citations
16.
Sun, Guangshun, Liangliang Wu, Guoqiang Sun, et al.. (2021). WNT5a in Colorectal Cancer: Research Progress and Challenges. Cancer Management and Research. Volume 13. 2483–2498. 15 indexed citations
17.
Li, Zhitao, Guoqiang Sun, Guangshun Sun, et al.. (2021). Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges. Frontiers in Oncology. 11. 771335–771335. 29 indexed citations
18.
Hao, Xiaopei, Guangshun Sun, Yao Zhang, et al.. (2021). Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges. Frontiers in Cell and Developmental Biology. 9. 775462–775462. 110 indexed citations
19.
Mei, Jie, Xiaorui Liu, Guangshun Sun, et al.. (2019). Comprehensive analysis of peroxiredoxins expression profiles and prognostic values in breast cancer. Biomarker Research. 7(1). 16–16. 25 indexed citations
20.
Sun, Guangshun, Jingbo Pi, & Qiufan Zheng. (1995). [The study of GST mu gene deletion as the hereditary marker for susceptibility to lung cancer].. PubMed. 18(3). 167–9, 191. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wubin Zheng Breakdown of academic impact, for papers by Haihua Qian Breakdown of academic impact, for papers by Xiangyuan Luo Breakdown of academic impact, for papers by Peishan Hu Breakdown of academic impact, for papers by Sorin Armeanu–Ebinger Breakdown of academic impact, for papers by Tongyue Zhang Breakdown of academic impact, for papers by Zhouyu Ning Breakdown of academic impact, for papers by Alisha M. Mendonsa Breakdown of academic impact, for papers by Huizhen Suo Breakdown of academic impact, for papers by Taisuke Kawamoto
Rankless by CCL
2026